The Swiss market has had a mixed performance in recent days, with the benchmark SMI index experiencing volatility and closing slightly lower, while some companies such as Relief Therapeutics posted strong gains. . In this dynamic environment, identifying high-growth Swiss tech stocks can be a strategic move for investors looking to leverage innovation and resilience amid market volatility to strengthen their portfolios. there is.
Top 10 high-growth technology companies in Switzerland
name
increase in revenue
revenue growth
growth assessment
LEM Holding
8.81%
20.48%
★★★★★☆
Sunterra Pharmaceuticals Holding
26.80%
35.40%
★★★★★
ALSO Holdings
12.58%
26.76%
★★★★☆
comet holding
20.06%
48.34%
★★★★★
Temenos
7.58%
14.39%
★★★★☆
Software One Holding
8.55%
52.33%
★★★★★☆
Addex Therapeutics
26.51%
33.31%
★★★★★☆
Basilea Pharmaceutica
9.24%
33.25%
★★★★★☆
Sensirion Holdings
13.86%
102.68%
★★★★☆
MCH Group
4.41%
100.62%
★★★★☆
Click here to see the complete list of 12 stocks in SIX Swiss Exchange’s High Growth Technology Stocks and AI Stock Screener.
Here’s a look at some of the choices from the screener.
Simply Wall Street Growth Rating: ★★★★★☆
Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company developing oncology and anti-infective products with a market capitalization of CHF 545.45 million.
Business Operations: The Company derives its revenues primarily from the discovery, development and commercialization of innovative medicines, amounting to CHF 149.02 million. Its focus is on addressing medical needs in oncology and anti-infective diseases.
Swiss biotechnology company Basilea Pharmaceutica recently raised its 2024 sales and profit forecasts to CHF 203 million and CHF 60 million, respectively, indicating solid business growth. This upward revision follows important regulatory advances such as the extension of the approval of Cresemba® for pediatric use by the EC, enhanced market exclusivity until October 2027, and a milestone of CHF 10 million from Pfizer. Payment was also secured. Although mid-year sales fell to CHF 76.29 million from CHF 84.91 million a year earlier, Basilea remains strategically focused on expanding indications for its main products and remains well positioned in Switzerland’s high-growth technology sector. is building. The company’s commitment to research and development is evidenced by a significant increase in profitability over the next three years, with revenue expected to grow at an annual rate of 9.2%, faster than the overall Swiss market growth rate of 4.2%.
story continues
SWX:BSLN revenue and expense breakdown (as of October 2024)
Simply Wall Street Growth Rating: ★★★★★☆
Overview: LEM Holding SA and its subsidiaries specialize in providing solutions for measuring electrical parameters across various regions including China, Japan, Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA, and Latin America. It has a market capitalization of CHF 1.41 billion.
Business Operations: The company is focused on providing electrical measurement solutions globally, with significant operations spanning Asia, Europe and the Americas. The company operates in a market of CHF 1.41 billion.
Despite a difficult quarter in which sales fell from CHF 112.34 million to CHF 80.96 million and net profit fell from CHF 20.54 million to CHF 4.78 million, LEM Holding continued to improve on expectations for the Swiss market. It is expected that profits will grow by 20.5% per year, exceeding the previous year’s forecast, and the outlook is for recovery. 11.6%. This resilience is underpinned by a strong research and development focus, which is essential to remain competitive in the Swiss technology industry, where innovation drives success. The company’s strategic focus on R&D investment is consistent with expected annual revenue growth of 8.8%, twice the national average of 4.2%, and the company has the potential to outperform sectoral trends despite recent setbacks. It shows.
SWX:LEHN earnings and revenue growth (as of October 2024)
Simply Wall Street Growth Rating: ★★★★☆
Overview: Temenos AG, with a market capitalization of CHF 4.65 billion, develops, markets and sells integrated banking software systems for financial institutions worldwide.
Business Operations: The Company primarily generates revenues through its Products segment, which represents approximately $880 million, and its Services segment, which represents approximately $133 million.
Swiss tech company Temenos is poised for strong growth, outpacing the domestic market’s 11.6%, with revenue expected to rise 14.4% annually. This growth trajectory is supported by a significant commitment to research and development, which not only drives innovation but also strengthens our competitive advantage in the rapidly evolving software industry. Recent strategic hires and leadership changes highlight Temenos’ focus on integrating AI and cloud technologies to expand its global footprint and effectively serve the diverse needs of the financial sector. I am. Furthermore, reflecting its confidence in its financial health and future prospects, the company actively carried out share buybacks worth CHF 200 million between May and August 2024.
SWX:TEMN revenue and revenue growth (as of October 2024)
turn ideas into action
Interested in other possibilities?
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SWX:BSLN SWX:LEHN and SWX:TEMN.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
